See inside every stock. Pro
S&P 5007,624▼ 0.52%Nasdaq25,955▼ 0.21%Dow Jones52,215▼ 1.23%Nasdaq 10028,958▼ 0.00%VIX19.45▲ 2.21%US Dollar101.75▲ 0.14%Gold spot4,012▼ 0.30%WTI103.27▲ 3.82%
← ALAFY page
XStocksXray
Market X-Ray report · 23 October 2026

Afyren SAS (ALAFY)

Euronext Paris · France · prices in EUR · close of 23 Oct 2026

Key indicators

Last closeEUR 2.220
52-week range2.065 – 3.235
Return, 1 month / 3 months−12.8% / −21.4%
Return, 1 year / 3 years+0.0% / −40.0%
TrendBelow its 200-day average
RSI (14)39
Volatility (1 year)55.1%
Worst drawdown (1 year)-31.3%
Average daily value traded0.03M EUR
Dividend yield–

Market X-Ray price-based

50/ 100 · High confidence · ahead of 47% of stocks on this exchange
Trend43
Momentum60
Stability (higher is calmer)45
Liquidity50
Income–

Five-year price chart navy: price · brown: 200-day average

0.953.175.397.619.832021-112023-022024-052025-082026-10

About the company

Afyren is a French industrial biotechnology company that makes bio-based organic acids by fermenting plant-derived sugars rather than relying on petrochemical routes. Its main product is levulinic acid, which customers in the cosmetics, flavour and fragrance, and specialty chemical industries use as an ingredient and building block. The company is based in France and serves industrial clients seeking renewable alternatives to conventional chemicals.

On this site Afyren SAS appears as a stock on the Euronext Paris (France), code ALAFY, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

Summary

Afyren SAS (ALAFY) trades on the Euronext Paris in France. It last closed at EUR 2.220 on 23 October 2026.

Its price-based Market X-Ray is 50 out of 100 (a weak price profile), ranking 332 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.

Over the last year the price rose 0.0% and over the last three months it fell 21.4%. Returns are price returns, dividends not included.

Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.

stocksxray.com · page 1
XStocksXray
Afyren SAS (ALAFY)

The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris

Lens and metricValueScoreReading
Trend43 · WeakBelow its long-term averages and far from its highs.
Above 200-day average-17.6%
From 52-week high-27.2%
Momentum60 · FairTypical recent returns for this exchange.
3-month return-21.4%
6-month return6.0%
12-month return, skipping the last month14.6%
Stability (higher is calmer)45 · WeakVolatile, with deep drawdowns.
Volatility, 1 year (lower is calmer)55.1%
Worst drawdown, 1 year (smaller is calmer)-31.3%
Liquidity50 · FairModerate trading activity.
Average daily value traded0.03M EUR
Zero-volume days0.0%
Income–Pays no dividend.
Dividend yield–
Years with dividends0

Strengths

No lens stands out as a clear strength against its exchange.

Weak spots

  • Trend: Below its long-term averages and far from its highs.
  • Stability (higher is calmer): Volatile, with deep drawdowns.

Returns

1 week−3.5%
1 month−12.8%
3 months−21.4%
6 months+6.0%
1 year+0.0%
3 years−40.0%
5 years−72.3%

Signals

50-day / 200-day average2.567 / 2.694
Golden / death cross (60 days)Death, 16 days ago
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.084

Technical summary

DailyStrongly bearish0 bullish · 4 neutral · 12 bearish
WeeklyStrongly bearish0 bullish · 1 neutral · 11 bearish
MonthlyStrongly bearish1 bullish · 1 neutral · 6 bearish

How to read this report

Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.

stocksxray.com · page 2 · generated 24 Oct 2026